Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 13OTHER 7OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 11Gastrointestinal 9Genitourinary 8Breast 8CNS 5Tumor-Agnostic 4Thoracic 4Sarcoma 3Myeloid 3Endocrine 3Lymphoid 2Other solid neoplasm 1Other hematologic neoplasm 1NET 1

Conditions

Mesothelioma 1

Interventions

Cisplatin 28Irinotecan 18Gemcitabine 18Paclitaxel 14alvocidib 13Fluorouracil 11Oxaliplatin 10Cyclophosphamide 10Carboplatin 10Leucovorin 8Bortezomib 8Biopsy 8Taxes 7Radiotherapy 7Pemetrexed 7Magnetic Resonance Spectroscopy 7Doxorubicin 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7Specimen Handling 6tanespimycin 5Vorinostat 5LMB-100 5Early Intervention, Educational 5Bevacizumab 5temsirolimus 4sargramostim 4Sorafenib 4Sirolimus 4Platinum 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × olaparib × Other solid neoplasm × Clear all
NCT03531840 2021-04-09

Olaparib in People With Malignant Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
23 enrolled 16 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡